That company is Recursion Pharmaceuticals (NASDAQ: RXRX), and the Ark Genomic Revolution ETF currently owns over $50 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results